

Moving from Correlative Studies to Predictive Medicine

Richard Simon, D.Sc.
Chief, Biometric Research Branch
National Cancer Institute
<http://linus.nci.nih.gov/brb>

Disclosure Information

***AACR Molecular Diagnostics in Cancer Therapeutics
Development***

Richard Simon, D.Sc.

I have no financial relationships to disclose.

I will not discuss off label use and/or investigational use in my presentation.

“Biomarkers”

- Surrogate endpoints
 - A measurement made on a patient before, during and after treatment to determine whether the treatment is working
- Predictive classifier
 - A measurement made before treatment to predict whether a particular treatment is likely to be beneficial

Surrogate Endpoints

- It is extremely difficult to properly validate a biomarker as a surrogate for clinical outcome. It requires a series of randomized trials with both the candidate biomarker and clinical outcome measured
- Biomarkers for use in phase I/II studies need not be validated as surrogates for clinical outcome

Predictive Biomarkers

- Most cancer treatments benefit only a minority of patients to whom they are administered
 - Particularly true for molecularly targeted drugs
- Being able to predict which patients are likely to benefit would
 - save patients from unnecessary toxicity, and enhance their chance of receiving a drug that helps them
 - Help control medical costs

Oncology Needs Predictive Markers not Prognostic Factors

- Most prognostic factors are not used because they are not therapeutically relevant
- Most prognostic factor studies use a convenience sample of patients for whom tissue is available. Generally the patients are too heterogeneous to support therapeutically relevant conclusions

- Criteria for validation of surrogate endpoints should not be applied to biomarkers used in treatment selection

- Targeted clinical trials can be extremely more efficient than untargeted clinical trials, if we know who to target

- In new drug development, the role of a classifier is to select a target population for treatment
 - The focus should be on evaluating the new drug in a population defined by a predictive classifier, not on “validating” the classifier

Developmental Strategy (I)

- **Develop** a diagnostic classifier that identifies the patients likely to benefit from the new drug
- Develop a reproducible assay for the classifier
- **Use** the diagnostic to restrict eligibility to a prospectively planned evaluation of the new drug
- Demonstrate that the new drug is effective in the prospectively defined set of patients determined by the diagnostic

Develop Predictor of Response to New Drug

```
graph TD; A[Develop Predictor of Response to New Drug] --> B[Patient Predicted Responsive]; A --> C[Patient Predicted Non-Responsive]; B --> D[New Drug]; B --> E[Control]; C --> F[Off Study];
```

Patient Predicted Responsive

Patient Predicted Non-Responsive

New Drug

Control

Off Study

Evaluating the Efficiency of Strategy (I)

- Simon R and Maitnourim A. Evaluating the efficiency of targeted designs for randomized clinical trials. *Clinical Cancer Research* 10:6759-63, 2004.
- Maitnourim A and Simon R. On the efficiency of targeted clinical trials. *Statistics in Medicine* 24:329-339, 2005.
- reprints and interactive sample size calculations at <http://linus.nci.nih.gov/brb>

Comparison of Targeted to Untargeted Design


Simon R, Development and Validation of Biomarker Classifiers for Treatment Selection, JSPI

Treatment Hazard Ratio for Marker Positive Patients	Number of Events for Targeted Design	Number of Events for Traditional Design		
		Percent of Patients Marker Positive		
		20%	33%	50%
0.5	74	2040	720	316
0.67	200	5200	1878	820

- For Trastuzumab, even a relatively poor assay enabled conduct of a targeted phase III trial which was crucial for establishing effectiveness
- Recent results with Trastuzumab in early stage breast cancer show dramatic benefits for patients selected to express Her-2

You Can Evaluate How This Design Might Work For You

- <http://linus.nci.nih.gov/brb/>



Sample Size Calculation: Binary Outcome Endpoint

Evaluating the efficiency of targeted designs for randomized clinical trials and Supplement by Richard Simon and Aboubakar Maitournam. (Clinical Cancer Research 10:6759-6763, 2005)

pc

gamma

delta1

delta0

alpha

power

pc = probability of "response" for control arm

gamma = proportion of patients who are classifier negative (i.e. less responsive to new treatment)

delta1 = improvement in response probability for new treatment in classifier positive patients


delta0 = improvement in response probability for new treatment in classifier negative patients

alpha = two-sided significance level

© NIH, 2006

Developmental Strategy (II)

Develop Predictor of
Response to New Rx



Developmental Strategy (II)

- Do not use the diagnostic to restrict eligibility, but to structure a prospective analysis plan.
- Compare the new drug to the control overall for all patients ignoring the classifier.
 - If $p_{\text{overall}} \leq 0.04$ claim effectiveness for the eligible population as a whole
- Otherwise perform a single subset analysis evaluating the new drug in the classifier + patients
 - If $p_{\text{subset}} \leq 0.01$ claim effectiveness for the classifier + patients.

Key Features of Design (II)

- The purpose of the RCT is to evaluate treatment T vs C overall and for the pre-defined subset; not to re-evaluate the components of the classifier, or to modify or refine the classifier

The Roadmap

1. Develop a completely specified genomic classifier of the patients likely to benefit from a new drug
2. Establish reproducibility of measurement of the classifier
3. Use the completely specified classifier to design and analyze a new clinical trial to evaluate effectiveness of the new treatment with a pre-defined analysis plan.

Guiding Principle

- The data used to develop the classifier must be distinct from the data used to test hypotheses about treatment effect in subsets determined by the classifier
 - Developmental studies are exploratory
 - Studies on which treatment effectiveness claims are to be based should be definitive studies that test a treatment hypothesis in a patient population completely pre-specified by the classifier

Use of Archived Samples

- From a non-targeted “negative” clinical trial to develop a binary classifier of a subset thought to benefit from treatment
- Test that subset hypothesis in a separate clinical trial
 - Prospective targeted type (I) trial
 - Prospective type (II) trial
 - Using archived specimens from a second previously conducted clinical trial

Development of Genomic Classifiers

- Single gene or protein based on knowledge of therapeutic target
- Single gene or protein culled from set of candidate genes identified based on imperfect knowledge of therapeutic target
- Empirically determined based on correlating gene expression to patient outcome after treatment

Development of Genomic Classifiers

- During phase II development or
- After failed phase III trial using archived specimens.
- Adaptively during early portion of phase III trial.

Adaptive Signature Design

An adaptive design for generating and prospectively testing a gene expression signature for sensitive patients

Boris Freidlin and Richard Simon

Clinical Cancer Research 11:7872-8, 2005

Adaptive Signature Design

End of Trial Analysis

- Compare E to C for **all patients** at significance level 0.04
 - If overall H_0 is rejected, then claim effectiveness of E for eligible patients
 - Otherwise

- Otherwise:
 - Using only the first half of patients accrued during the trial, develop a binary classifier that predicts the subset of patients most likely to benefit from the new treatment E compared to control C
 - Compare E to C for patients accrued in second stage who are predicted responsive to E based on classifier
 - Perform test at significance level 0.01
 - If H_0 is rejected, claim effectiveness of E for subset defined by classifier

Collaborators

- Boris Freidlin
- Aboubakar Maitournam
- Yingdong Zhao

Simon R. Using DNA microarrays for diagnostic and prognostic prediction. *Expert Review of Molecular Diagnostics*, 3(5) 587-595, 2003.

Simon R. Diagnostic and prognostic prediction using gene expression profiles in high dimensional microarray data. *British Journal of Cancer* 89:1599-1604, 2003.

Simon R and Maitnourim A. Evaluating the efficiency of targeted designs for randomized clinical trials. *Clinical Cancer Research* 10:6759-63, 2004.

Maitnourim A and Simon R. On the efficiency of targeted clinical trials. *Statistics in Medicine* 24:329-339, 2005.

Simon R. When is a genomic classifier ready for prime time? *Nature Clinical Practice – Oncology* 1:4-5, 2004.

Simon R. An agenda for Clinical Trials: clinical trials in the genomic era. *Clinical Trials* 1:468-470, 2004.

Simon R. Development and Validation of Therapeutically Relevant Multi-gene Biomarker Classifiers. *Journal of the National Cancer Institute* 97:866-867, 2005.

Simon R. A roadmap for developing and validating therapeutically relevant genomic classifiers. *Journal of Clinical Oncology* 23(29), 2005.

Freidlin B and Simon R. Adaptive signature design. *Clinical Cancer Research* 11:7872-8, 2005.

Simon R. Guidelines for the design of clinical studies for development and validation of therapeutically relevant biomarkers and biomarker classification systems. In *Biomarkers in Breast Cancer*, Hayes DF and Gasparini G, Humana Press, pp 3-15, 2005.

Simon R and Wang SJ. Use of genomic signatures in therapeutics development in oncology and other diseases. *The Pharmacogenomics Journal*, 2006.